

*Hong Kong Exchange and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



# 石四藥集團有限公司 SSY Group Limited

*(Incorporated in the Cayman Islands with limited liability)*  
**(Stock Code: 2005)**

## **UNAUDITED OPERATING RESULTS FOR THE THREE MONTHS ENDED 31 MARCH 2024**

This announcement is made by SSY Group Limited (the “Company”) pursuant to Inside Information Provisions (as defined under the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “Listing Rules”)) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) and Rule 13.09(2) of the Listing Rules.

The board of directors (the “Board”) of the Company is pleased to announce the following unaudited operating results of the Company and its subsidiaries (together, the “Group”) for the three months ended 31 March 2024 based on its management accounts which have not been audited or reviewed by the auditor of the Company.

Majority of the Group’s sales are conducted in the PRC and are denominated in Renminbi (“RMB”), which depreciated by approximately 3.6% when translated into Hong Kong dollars (“HK\$”) for the three months ended 31 March 2024 as compared with the same period of 2023. As a result, in terms of HK\$, the unaudited turnover of the Group for the three months ended 31 March 2024 increased only by 2.9% as compared with the same period of 2023 to approximately HK\$1,799 million (same period of 2023: approximately HK\$1,749 million). The unaudited gross profit of the Group for the three months ended 31 March 2024 increased by 2.3% to approximately HK\$1,031 million (same period of 2023: approximately HK\$1,008 million). The unaudited gross profit margin of the Group for the three months ended 31 March 2024 was approximately 57.3%, representing a slight drop of 0.3 percentage point as compared with the same period of 2023. For the three months ended 31 March 2024, the Group’s unaudited profit attributable to the shareholders of the Company (the “Shareholders”) increased by approximately 14.6% as compared with the same period of 2023 to approximately HK\$416 million (same period of 2023: approximately HK\$363 million).

For the three months ended 31 March 2024, the abovementioned unaudited turnover of the Group of approximately HK\$1,799 million was comprised of the following:

| <b>For the three months ended 31 March 2024</b>          | <b>Unaudited turnover (HK\$)</b> | <b>Increase/ (decrease) from same period of 2023</b> | <b>% of unaudited turnover</b> |
|--|----------------------------------|--|--------------------------------|
| IV solution products (including subcontracting products) |                                  |  |                                |
| Non-PVC soft bag IV solution                             | 521 million                      | (10.3)%  | 29.0%                          |
| Upright soft bag IV solution                             | 272 million                      | 48.2%  | 15.1%                          |
| PP plastic bottle IV solution                            | 228 million                      | 0.4%   | 12.6%                          |
| Glass bottle IV solution                                 | 44 million                       | (26.5)%  | 2.5%                           |
| Non-IV solution products                                 |                                  |  |                                |
| Ampoule injection  | 280 million                      | 5.0%   | 15.6%                          |
| Bulk pharmaceuticals                                     | 234 million                      | 5.9%   | 13.0%                          |
| Oral preparations  | 147 million                      | (0.4)%   | 8.2%                           |
| Medical materials  | 47 million                       | 8.0%   | 2.6%                           |
| Other products and services                              | 26 million                       | 38.6%  | 1.4%                           |

**Shareholders and potential investors should note that all financial information contained in this announcement is unaudited. Accordingly, such information shall in no way be regarded as to provide any indication of the audited financial results of the Group for the three months ended 31 March 2024 or any assurance on such audited financial results. Such information may differ from the information to be disclosed in the audited or unaudited consolidated financial statements to be published by the Company on an annual or half-yearly basis due to various uncertainties during the process of compiling such operating results information.**

**Shareholders and potential investors are advised to exercise caution in dealing in the securities of the Company.**

By order of the Board  
**Chow Hing Yeung**  
*Executive Director and Company Secretary*

Hong Kong, 16 April 2024

*As at the date of this announcement, the Board comprises Mr. Qu Jiguang, Mr. Su Xuejun, Mr. Meng Guo and Mr. Chow Hing Yeung as executive Directors, Mr. Liu Wenjun as non-executive Director and Mr. Wang Yibing, Mr. Chow Kwok Wai and Mr. Jiang Guangce as independent non-executive Directors.*